Skip to content

An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial.

Francesco Pagnini, Deborah Phillips, Anne Haulman, Matthew Bankert, Zachary Simmons, Ellen J. Langer

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration February 2022 DOI: 10.1080/21678421.2021.1928707 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 74
Population ALS patients and their caregivers recruited from the ALS clinic at Penn State Health and online
Intervention Langerian mindfulness training program
Duration 5-week program with 3- and 6-month follow-ups
Topics Meditation
Keywords Amyotrophic lateral sclerosis Caregivers Psychological intervention Quality of life
Key findings The authors report that a 5-week online Langerian mindfulness program increased quality of life in ALS patients (d = 0.54 at end of treatment) and reduced depression, anxiety, and negative emotions over time, while caregivers showed lower care burden, depression, and anxiety and higher energy and emotional well-being. They characterize this as preliminary evidence from a small trial.

Abstract

Objectives: Mindfulness-based interventions seem to be effective in promoting QOL of ALS patients and caregivers, but most require substantial time. In the Langerian approach, mindfulness can be easily promoted with mental tasks and short lectures. This study aims to explore the impact of an ALS-specific online Langerian mindfulness training program on QOL of ALS patients.

Methods: We developed and tested with an Randomized Controlled Trial (RCT) a 5-week active learning mindfulness program. Participants were recruited from the ALS clinic at Penn State Health and online and were randomly assigned to either the mindfulness group or a wait-list control group. The primary outcome was the patient's QOL after the treatment. 3 and 6-month follow-ups, together with anxiety, depression, care burden, and physical function, assessed at all times for both patients and caregivers, were explored as secondary outcomes.

Results: 47 ALS patients and 27 caregivers were recruited. Among the ALS patients, the experimental group reported higher levels of QOL at the end of the treatment (d = 0.54). Moreover, they showed lower values of depression, anxiety, and negative emotions, compared to the controls, over time. The caregivers from the mindfulness group reported lower scores of care burden, depression, and anxiety, with higher values of energy and emotional well-being over time.

Conclusions: This small RCT provides preliminary evidence that this intervention leads to an increase of QOL and a reduction in psychological comorbidities in ALS patients and caregivers. Given the relatively short time commitment, it may be easily implemented by the ALS community.

Comparable studies

Other randomized controlled trials on meditation, most cited first.

Study Year Design Participants
Alterations in Brain and Immune Function Produced by Mindfulness Meditation Healthy employees in a work environment 2003 Randomized controlled trial n = 41
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Open hearts build lives: Positive emotions, induced through loving-kindness meditation, build consequential personal resources. Working adults 2008 Randomized controlled trial n = 139
Short-term meditation training improves attention and self-regulation Undergraduate Chinese students 2007 Randomized controlled trial n = 40
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics